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CD46 (Membrane Cofactor Protein) Acts as a Human
Epithelial Cell Receptor for Internalization of Opsonized
Uropathogenic Escherichia coli1
Ke Li,* Maria Jose Feito,† Steven H. Sacks,* and Neil S. Sheerin2*
Escherichia coli is a common urinary pathogen whose uptake into epithelial cells is mediated by attachment through type 1
fimbriae. In this study, we show by using using human urinary tract epithelial cells that maximal internalization of E. coli is
achieved only when bacteria are opsonized with complement. The concentrations of complement proteins in the urine rise suf-
ficiently during infection to allow bacterial opsonization. The complement regulatory protein, CD46 (membrane cofactor protein),
acts in cohort with fimbrial adhesion to promote the uptake of pathogenic E. coli. This uptake is inhibited by RNA interference
to lower the expression of CD46 and by soluble CD46 that will competitively inhibit opsonized bacteria binding to cell surface
CD46. We propose that efficient internalization of uropathogenic E. coli by the human urinary tract depends on cooperation
between fimbrial-mediated adhesion and C3 receptor (CD46)–ligand interaction. Complement receptor–ligand interaction could
pose a new target for interrupting the cycle of reinfection due to intracellular bacteria. The Journal of Immunology, 2006, 177:
2543–2551.
B acterial infection of the urinary tract is a common clinicalproblem, estimated to affect 40–50% of women at leastonce in their lifetime, 20% of whom will develop recur-
rent infections (1). The most important causative organism is Esch-
erichia coli (E. coli), which is responsible for 70–80% of all uri-
nary tract infections (UTIs).3 E. coli has several well-recognized
characteristics that increase its virulence, such as fimbrial adhesins
(type 1, P, S, and Dr fimbriae) and toxins (-hemolysin, cytotoxic
necrotizing factor 1). In addition, uropathogenic strains are usually
resistant to serum bactericidal activity (2). Perhaps less well un-
derstood is how host factors influence disease outcome. Under-
standing the interactions between E. coli and host-defense mech-
anisms may provide new insight into the success of this organism
and provide a rationale for immune-based therapies for disease
prevention.
The epithelial cell lining of the urinary tract is the first point of
contact for potential pathogens. The ability of uroepithelial cells to
internalize bacteria has been recognized for some time (3). Epi-
thelial cells from both the kidney (3–5) and the bladder (6–8) have
the capacity to internalize bacteria into membrane-bound vacuoles.
The importance of bacterial fimbriae, particularly type 1 fimbriae,
in this process has been demonstrated (9). Internalization is in-
creasingly recognized as an important feature of bacterial infec-
tion. It can enhance bacterial survival by providing protection from
host immune defenses and allow pathogens greater access to
deeper tissues. A recent study also has shown that intracellular E.
coli can form a reservoir within the bladder mucosa that may serve
as a source for recurrent acute infections, a well-recognized clin-
ical problem (10).
However, the uroepithelial cell is not simply a passive target for
infection but may actively participate in the innate immune re-
sponse. Epithelial cells have the capacity to produce chemotactic
cytokines (11), enhancing neutrophil recruitment, and also can
produce components of the complement system, including C3
(12, 13).
Complement is an important element in the innate immune re-
sponse against many bacterial pathogens. Several observations
suggest that complement plays an important role in the pathogen-
esis of ascending UTI. First, production of complement proteins
within the kidney is increased in response to cytokines associated
with acute infection (14, 15). Second, most uropathogens are re-
sistant to killing by complement, suggesting evolutionary pressure
on bacteria to develop resistance. Third, previous studies have
shown that decomplementation by cobra venom factor (CVF) de-
creases the degree of tissue damage during renal infection (16–18).
Furthermore, we reported recently that mice deficient in C3, the
pivotal component of the complement cascade, are resistant to as-
cending infection (19). This may, in part, be explained by the
observation that, in vitro, bacteria coincubated with serum were
internalized by mouse proximal tubular epithelial cells at a rate
10-fold higher than that of nonopsonized bacteria.
Human cells express both complement receptors (CR) and reg-
ulatory proteins, both of which have the capacity to bind to C3 and
mediate signal transduction. C3 is deposited on the surface of
pathogens, acting as a ligand for receptors on phagocytic leuko-
cytes. Less is known about the ability of C3-opsonized pathogens
to interact with receptors on epithelial cells, and the functional
consequence of such C3-receptor–ligand interaction. Colonic and
cervical epithelial cells can internalize opsonized HIV (20) and
Neisseria gonorrhoea (21), respectively. This occurs through bind-
ing to CR3. However, these receptors have limited distribution and
have not been identified on renal tract epithelial cells.
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In contrast, complement regulatory proteins, such as CD46 and
CD55, are ubiquitous. CD46, membrane cofactor protein, is the
cellular receptor for several pathogens, including Neisseria men-
ingitidis (22), measles virus (23), human HSV 6(24), group A
Streptococci (25), and group B adenovirus (26). For many of these
pathogens, binding to CD46 leads to internalization and mediates
increased pathogenicity. These pathogen–CD46 interactions rely
on specific pathogen-expressed proteins rather than host-derived
C3. However, a recent report has suggested that opsonized Kleb-
siella may interact with pulmonary epithelial cells via CD46(27).
CD55 is bound directly by Dr fimbriated uropathogenic E. coli, a
pathogen particularly associated with ascending UTI during preg-
nancy (28).
In the present study, we have examined the relationship between
human renal tract epithelial cells and opsonized uropathogenic E.
coli. We report that the mechanism for bacterial invasion of human
bladder and renal tubular epithelial cells is complement dependent.
Moreover, we find that CD46 expressed on epithelial cells plays a
critical role in the internalization process. Finally, we demonstrate
that infected urine contains sufficient quantities of C3 to allow this
CD46-mediated internalization.
Materials and Methods
Bacteria and cells
The uropathgenic E. coli strain J96 was provided by Dr. R. Welch, (Uni-
versity of Wisconsin, Madison, WI). It is a serum-resistant, hemolysin-
secreting E. coli strain that expresses both type 1 and P fimbriae (29). A Dr
fimbriated pyelonephritic strain IH11128 (O75:K5:H) was provided by
Dr. B. Nowicki (University of Texas, Galveston, TX). Infected urine sam-
ples were obtained from the Department of Microbiology, St. Guy’s and St.
Thomas’ National Health Service Foundation Trust (London, U.K.). Bac-
teria were grown in 10 ml of static Luria-Bertani broth at 37°C for 16 h
before use in experiments. For each experiment, bacterial concentration
was standardized by photospectrometry at 600 nm, and colony numbers
were confirmed by using serial dilutions and plating to agar plates. The
human PTEC line was a gift from Dr. L. C. Racusen (Johns Hopkins Uni-
versity School of Medicine, Baltimore, MD) (30). The cells were grown in
DMEM-F12 supplemented with 5% FCS, 5 g/ml insulin, 5 g/ml trans-
ferin, 5 ng/ml sodium selenium, 100 U/ml penicillin, and 100 g/ml
streptomycin. The bladder epithelial cell line J82 was obtained from the
American Type Culture Collection. Cells were grown in Eagle’s min-
imum essential medium with nonessential amino acids and sodium
pyruvate supplemented with 10% FCS, 2 mM glutamine, 100 U/ml
penicillin, and 100 g/ml streptomycin.
Complement, complement buffers, and complement inactivation
Normal human serum (NHS) was obtained from five healthy volunteers.
After collection, serum was pooled and stored at 70°C for up to 3 mo.
Complement activation experiments were performed in GVBS buffer
(Veronal-buffered saline (VBS) with 0.1% gelatin, 0.15 mM CaCl2, and 1.0
mM MgCl2), in which all complement pathways are active. EDTA-
GVBSbuffer (VBS with 0.01M EDTA) inhibits all complement path-
ways. Complement activity in serum was inactivated by incubation at 56°C
for 30 min (heat-inactivated serum, HINHS). Alternatively, C3 in serum
was depleted by treatment with CVF by incubating 1 ml of NHS with 20
g of CVF at 37°C for 60 min (31). Complement inactivation was con-
firmed by loss of hemolytic activity using standard methodology (data not
shown).
FACS analysis of complement fragment deposition
Bacteria were opsonized as described previously (32). Briefly, 2  108
CFU J96 were washed and then incubated in GVBS containing 5%
NHS, HINHS, or CVF-treated NHS at 37°C for 20 min. Bacteria were
washed and then stained with rabbit anti-human C3 (1/100 dilution; Sero-
tec) or mouse monoclonal anti-human complement fragments iC3b (cross-
reactive with C3b) and anti-human C4d (10 g/ml; Quidel) for 1 h at 25
oC. Bacteria were washed again and then stained with FITC-labeled sec-
ondary Abs (goat anti-rabbit IgG (1/100 dilution; Serotec) or goat anti-
mouse IgG (1/100 dilution; Sigma-Aldrich). After washing, bacteria were
fixed with 1% paraformaldehyde and analyzed by flow cytometry. The
intensity of staining for C3 was analyzed using CellQuest software (BD
Biosciences), using the median cell fluorescence as a measure of staining
intensity (median fluorescence intensity).
Timecourse of C3 activation and degradation
The kinetics of C3 activation and degradation was assessed by C3 Western
blotting. First, J96 were incubated with 5% NHS in GVBS buffer at
37oC for varying time points. At the end of the incubation period, the
bacteria were washed in EDTA-GVBS to stop further complement acti-
vation. Bacterial-bound complement proteins were eluted with 4 mM so-
dium carbonate and 46 mM sodium bicarbonate (pH 9.2) for 2 h at 37°C.
FIGURE 1. C3 opsonization of
uropathogenic E. coli. C3 is depos-
ited on the surface of uropathogenic
E. coli in a serum concentration-de-
pendent manner (A). C3 Western blot
shows the quantities of C3b (
chain, 105 kDa) and iC3b (1 chain,
67 kDa; 2 chain, 40 kDa) on bacte-
ria over time in 5% NHS (B). Purified
C3b (0.2 g) is included for control.
Molecular mass markers (in kDa) are
indicated on the left side of the panel.
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Bacteria were removed by centrifugation. Eluted proteins were separated
by 10% SDS-PAGE under reducing conditions and transferred to a Hy-
bound-c Extra membrane (Amersham Biosciences). The membrane was
sequentially incubated with blocking buffer at 4°C overnight, rabbit anti-
human C3c (1/1000; DakoCytomation), and peroxidase-conjugated goat
anti-rabbit IgG (1/5000; DakoCytomation). The membrane was then de-
veloped using the ECL system (Amersham Biosciences).
Detection of urinary C3
Urine samples were collected from patients with acute UTI (provided by
the Department of Microbiology, St. Guy’s and St. Thomas’ National
Health Service Trust) and healthy volunteer controls (six samples). The
healthy volunteer and patient groups were of similar age and were sex
matched. C3 concentration was measured by ELISA as described previ-
ously (33). In brief, 96-well plates (Nunc) were coated overnight at 4°C
with sheep anti-human C3c (The Binding Site) diluted 1/200 in PBS. After
blocking with PBS containing 1% BSA, the plate was incubated with ap-
propriately diluted urine samples, followed by rabbit anti-human C3c (Da-
koCytomation) diluted 1/3000, then peroxidase-conjugated goat anti-rabbit
IgG (DakoCytomation) diluted 1/5000. Each Ab incubation was performed
in 100 l of PBS containing 1% BSA, 0.1% Tween at 37oC for 1 h, and
followed by washing in PBS containing 0.1% Tween. The enzyme activity
was read after incubation with O-phenylenediamine by measuring absor-
bance at 490 nm. Purified C3 (1.0 mg/ml; Quidel) was used to generate a
standard curve. The limit of sensitivity of this assay was 0.1 ng/ml. Urinary
proteins also were separated by 10% SDS-PAGE under reducing condi-
tions and Western blotted as above.
Electron microscopy (EM)
PTECs were grown on glass coverslips and infected with E. coli J96 for
3 h. After washing, cells were prefixed in 2.5% glutaraldehyde in PBS,
washed, and postfixed with 1% osmium tetroxide. For scanning EM, cells
were dried using a critical point dryer to achieve minimal cell distortion.
Cells were then coated with gold and examined using a scanning electron
microscope (model S520; Hitachi) at 15 kV of accelerating voltage. For
transmission EM, fixed cells were dehydrated in increasing concentrations
of ethanol at 60°C, postfixed, stained with lead citrate, and viewed on a
transmission electron microscope (model H7000; Hitachi).
Assessment of bacterial binding and internalization
Epithelial cells were seeded into 24-well plates and grown to confluence.
Overnight cultures of J96 were adjusted to an OD of 0.01 at 600 nm (1 
107 CFU/ml). Culture medium was replaced with 900 l of prewarmed
DMEM-F12 in the presence of 5% NHS or HINHS, and epithelial cells
were infected with 100 l of the bacterial suspension. Bacterial contact
with host cells was increased by centrifugation of plates at 600  g for 5
min. After 3 h of incubation at 37°C, the total number of bacteria present
and the number of bacteria bound to and internalized by cells were mea-
sured in wells run in parallel. Total bacterial number was measured by
adding 2 lysis buffer (2% Triton X-100) to each well and plating out
lysate. Bacteria bound to PTECs were measured by lysing cells after vig-
orous washing to remove unattached bacteria. This would include inter-
nalized bacteria, but because binding exceeded internalization by 100-
fold, no correction was made. The percentage of bacteria bound was
calculated as the number of bacteria bound to the epithelial cell monolayer
divided by the total number of bacteria present. To assess the number of
internalized bacteria, after washing, the cells were incubated for 1 h in
medium containing 100 g/ml gentamicin to kill extracellular bacteria,
then lysed. The percentage of bacteria internalized was calculated as the
number of bacteria surviving incubation with gentamicin divided by the
total number of bacteria present.
To determine whether the presence of serum acted through bacterial
opsonization or altered PTEC phenotype, bacteria or cells were pre-ex-
posed to 5% NHS or HINHS for 1 h at 37oC. The rate of internalization
was then measured as described above but in the absence of additional
serum.
Detection and reduction in cell expression of CD46 and CD55
The expression of CD46 and CD55 was detected by FACS and immuno-
cytochemistry using rabbit anti-CD46 and rabbit anti-CD55 (obtained from
Dr. J. Atkinson and Dr. D. Lublin, Washington University School of Med-
icine, St. Louis, MO, respectively). To silence CD46 expression PTECs
(seeded in a 24-well plate) were transfected with short interfering RNA
(siRNA) (sense sequence: 5-GGAGCCACCAACAUUUGAATT-3; anti-
sense sequence: 5-UUCAAAUGUUGGUGGCUCCTC-3) or silencer
negative control siRNA (Ambion Europe) using an siRNA transfection kit
(siPORT Amine; Ambion). After 48 h, mRNA degradation and reduction
in proteins synthesis were confirmed by RT-PCR (5-GCTGCTCCAG
AGTGTAAAGTGG-3 and 5-AACAATCACAGCAATGACCC-3) and
Western blotting (using rabbit anti-CD46). Image J software (National In-
stitutes of Health, Bethesda, MD) was used to quantify band intensity on
PCR gels and Western blots. Transfected cells were further used for bac-
terial binding and internalization assays.
To reduce surface expression of CD55, PTECs were treated enzymati-
cally to remove GPI-linked membrane proteins. PTECs (seeded in 24-well
plate) were incubated with 500 l of PBS containing varying concentra-
tions of phosphatidylinositol-specific phospholipase C (PI-PLC; BIOMOL)
at 37°C for 1 h. PI-PLC-treated cells were further used for bacterial inter-
nalization assay.
Soluble CD46 competition assays
Soluble CD46 (generated from MCP-C2 isoform, a gift from Dr. J. Rojo,
Centro de Investigaciones Biolo´gicas, Consejo Superior de Investigaciones
Cientificas, Madrid, Spain; Ref. 27) at a final concentration of 100 g/ml
was added to PTECs with bacteria and serum, and the internalization assay
continued as described above. BSA was used in control experiments.
Statistical analysis
Data were analyzed by Student’s t test for comparison of two variables,
ANOVA with Bonferroni posttest for multiple comparisons, Mann-Whit-
ney U test or Fischer’s exact test. Values of p  0.05 were regarded as
significant.
Results
Opsonization of bacteria by complement, in particular, the pivotal
component C3, is a fundamental element of the innate immune
response against infection. When the uropathogenic E. coli strain
J96 was exposed to NHS, there was rapid opsonization with C3
protein in a concentration-dependent manner, with maximum op-
sonization seen at serum concentrations 10% (Fig. 1a). To find
out the kinetics of C3 activation and degradation, we have per-
formed C3 Western blotting using elute from bacteria incubated
FIGURE 2. Binding of C3 opsonized bacteria to host epithelial cells. A,
Bacteria can be seen bound to the surface of tubular epithelial cells (scale
bar, 2 m). B, Significantly more bacteria bound to cells in the presence of
5% NHS, compared with 5% HINHS (p  0.05). The number of bacteria
binding to PTEC also was assessed after pre-exposure of bacteria (C) or
PTEC (D) to 5% NHS (n  4 per experiment). Results are representative
of three separate experiments.
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with 5% NHS for varying time points. Maximal C3b deposition on
E. coli was achieved at 5 min and persisted for up to 3 h. iC3b was
evident after 1 min, the amount increasing with time (Fig. 1b). C3b
and iC3b are the major forms of C3 deposited on E. coli surface.
These C3 opsonins can potentially interact with a broad range of
host membrane complement binding proteins including C3 regu-
latory proteins and the CR1–CR4. J96 is not sensitive to comple-
ment-dependent lysis, with no reduction in the number of viable
bacteria in serum concentrations up to 50%.
Complement opsonization increases bacterial binding to tubular
epithelial cells
Binding of uropathogenic bacteria to renal tract epithelium is crit-
ical for bacterial persistence in the urinary tract and therefore for
infection. The E. coli strain J96 binds to tubular epithelial cells.
However, binding was increased by 10-fold if a source of com-
plement (5% NHS) was present throughout the assay (Fig. 2, a and
b). This effect required complement activity, as it was not seen
when the assay was performed in the presence of HINHS (1.75 
0.11 vs 0.13  0.02 bacteria bound per cell, NHS vs HINHS).
Preopsonization of the bacteria with complement before adding to
cells also increased bacterial binding (Fig. 2c), whereas pre-expo-
sure of epithelial cells had no effect (Fig. 2d), confirming that an
interaction between complement and the bacteria was essential for
this effect. Complement-mediated damage to the epithelial cell
during the assay was excluded by the absence of significant LDH
release from cells when incubated with NHS (data not shown).
This suggests that bacterium-bound complement acts a ligand
binding to an epithelial cell receptor, thereby increasing bacterial
binding.
Complement opsonization increases bacterial internalization by
tubular epithelial cells
Human tubular epithelial cells have the capacity to internalize bac-
teria. J96 is internalized by the human tubular epithelial cell line
used in this study. As with binding, if internalization is assessed in
the presence of NHS as a source of complement the rate of inter-
nalization is increased (Fig. 3, a and b). This occurred in a serum
FIGURE 3. Internalization of C3-opsonized bacteria
by epithelial cells. A, By TEM, bacteria could be seen
inside vacuoles within the cytoplasm of PTEC 3 h after
coincubation (scale bar, 2 m). The percentage of bac-
teria internalized by PTEC in the presence of 5% NHS
or HINHS was assessed (B) as well as the number of
bacteria internalized at different serum concentrations
(C). D, The effect of NHS on bacterial internalization
into the bladder epithelial cell line J82. The number of
bacteria internalized into PTEC also was assessed after
pre-exposure of bacteria (E) or PTEC (F) to 5% NHS
(n  4 per experiment). Results are representative of
three separate experiments.
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concentration-dependent manner, being evident at serum concen-
trations 1% (Fig. 3c). The effect of complement on internaliza-
tion was not unique to tubular epithelial cells. The same effect was
also seen with bladder epithelial cells (Fig. 3d) and glomerular
epithelial cells (data not shown).
As with bacterial binding to epithelial cells, the effect of com-
plement was due to opsonization of bacteria rather than an effect
on the epithelial cells. Pre-exposure of bacteria to complement
proteins led to an increase in bacterial internalization (Fig. 3e).
However, pre-exposure of epithelial cells had no effect on the rate
of bacterial internalization (Fig. 3f).
To confirm that this was a specific affect of complement acti-
vation, complement in serum was inactivated by CVF treatment.
CVF depletes C3 and therefore prevented C3 deposition on bac-
teria (Fig. 4a) but did not reduce the deposition of another potential
opsonin C4 (Fig. 4b). Pretreatment of NHS with CVF abolished its
ability to augment bacterial internalization by epithelial cells to the
level seen with HINHS (Fig. 4c). C4b did not substitute for C3b in
enhancing bacterial internalization, possibly due to lesser amounts
of C4b deposited on the bacterial surface in the absence of the
amplification provided by the alternative pathway.
Infected urine permits opsonization of pathogenic E. coli with C3
For this effect to be relevant to clinical infection. bacterial opso-
nization needs to occur within the urinary tract. C3 was detected in
the urine of patients with acute UTI by Western blotting. Intact C3
(- and -chains, 115 and 75 kDa, respectively) as well as the
activation product C3 2 was present in infected urine samples
(Fig. 5a, Lane 4). The C3 concentration (corrected for urinary
creatinine concentration) in the urine of 6 normal controls and 20
patients with active UTI are shown in Fig. 5b. There was a sig-
nificant increase of 15-fold in the mean C3/Cr ratio during in-
fection (mean 2.6 and 38.6 mg/mol Cr in control and infected
urine, respectively; p  0.005). The maximum C3 concentration
achieved was 14.4 g/ml, which equates to 1.4% of the C3 con-
centration in serum. This is above the level required for demon-
strable C3 opsonization of bacteria and suggests that sufficient C3
is present in urine to lead to functionally significant opsonization
of bacteria within the urinary space during infection.
We next determined whether urinary complement proteins can
opsonize bacteria. Cells and bacteria were removed from infected
urine by centrifugation. Laboratory grown bacteria (free from prior
contact with serum proteins) were then added to the cleared urine,
incubated at 37°C for 2 h, and then extensively washed. Surface-
bound C3 was eluted and Western blotted. C3 activation products
could be detected from the bacterial surface that must be derived
from the urine (Fig. 5a, Lane 5). These observations support the
ability for C3 opsonization of bacteria to occur during clinical
infection.
CR on epithelial cells
It is clear from these data that complement proteins on bacterial
surfaces can interact with ligands on epithelial surfaces. The mem-
brane expression of proteins capable of binding C3 was, therefore,
FIGURE 4. Bacterial internalization in CVF-treated serum. Bacteria
were incubated in NHS (thick line), HINHS (dotted line), or NHS depleted
of C3 by treatment with CVF (thin line). C3 opsonization of bacteria was
abolished by CVF treatment (A), but opsonization with C4 was increased
(B). Internalization also was assessed under these conditions (C). n 	 8,
p  0.005 for NHS vs. both HINHS and CVF-treated serum.
FIGURE 5. Detection of C3 in urine. C3 was detected in urine of pa-
tients with UTI. A, Western blot of C3 fragments is shown under reducing
conditions. Lanes 1 and 2, The fragment profile of intact and activated C3b
(0.2 g), respectively. Lane 3, Human serum (1/100 dilution, 0.1 g of
C3). Infected urine (1/5 dilution) was separated in Lane 4. Intact C3 (1,
15 kDa) is detected in serum and infected urine, in addition iC3b (1, 67
kDa; 2, 40 kDa) is detected, suggesting degradation of C3 to inactive
forms. Activated C3 forms C3b ( chain, 105 kDa) and iC3b (1, 67
kDa,;2, 40 kDa) were eluted from E. coli that had been incubated in the
same infected urine (Lane 5). The band at 75 kDa represents the C3
-chain. The C3/Cr ratio in urine of patients with UTI and healthy controls,
as measured by ELISA, is shown in B.
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determined. Both CD46 (Fig. 6, a and b) and CD55 (Fig. 6, c and
d) were present on the epithelial cell surface. However, CR1–CR4
were not detected on cells by FACS, and no evidence of gene
expression could be detected by RT-PCR (data not shown).
CD55 is not required for complement-mediated internalization
CD55 is a GPI-linked protein and can be removed from the cell
surface by treatment with PI-PLC (Fig. 7a). However, reduction in
the level of surface CD55 expression by 50% did not affect the
rate of bacterial internalization (Fig. 7b). One possible explanation
for this result is that, even at the highest concentration of PIPLC,
only 50% of the surface CD55 is removed. However, PI-PLC
treatment was sufficient to reduce the internalization of Dr fimbri-
ated strain 1H11128(34). This E. coli strain is dependent on Dr
fimbriae binding to CD55 to mediate internalization (Fig. 7c). This
would suggest that PI-PLC treatment does induce a functionally
significant reduction in cell surface CD55.
CD46 is required for complement-mediated internalization
A recent study has suggested that CD46 may be responsible for the
internalization of opsonized bacteria by lung epithelium. CD46 is
expressed widely throughout the urinary tract. CD46 expression on
tubular epithelial cells was reduced by transfection of cells with
CD46 siRNA. A reduction was observed at siRNA concentrations
25 nM, but silencing was most pronounced at 100 nM, reducing
mRNA levels by 45% and protein synthesis by 73% (Fig. 8, a and
b). Because CD46 is required to control complement activation, it
is possible that suppression of CD46 would lead to an increase in
cell damage when exposed to serum proteins. LDH release after
exposure to NHS did not differ from cells with suppressed CD46
expression, compared with that released by cells transfected with
a random sequence siRNA.
A significant reduction in the rate of internalization was seen
when CD46 levels were suppressed (Fig. 8c). There was an 8-
fold reduction in internalization, accounting for the majority of the
complement-mediated increase. The siRNA dose-dependent re-
duction in CD46 expression was mirrored by a reduction in bac-
terial internalization (Fig. 8d).
Purified soluble CD46 provided another means of blocking C3–
CD46 interactions. It binds C3b and, therefore, has the capacity to
competitively inhibit the interaction between C3 opsonic frag-
ments deposited on the bacterial surface and epithelial cell surface-
bound MCP. The addition of 100 g/ml CD46 led to a reduction
in the internalization of E. coli by 70.4%, whereas the presence of
BSA (used as a control) did not affect the rate of internalization
(Fig. 9a). C3 FACS analysis showed that incubation of bacteria
with serum in the presence of soluble CD46 did not affect C3
deposition, compared with bacteria incubated with serum alone
(Fig. 9b).
FIGURE 6. Demonstration of Complement Regulatory Proteins on the
surface of PTEC. CD46 and CD55 expression on the surface of PTEC were
demonstrated by FACS (A and C, respectively). Control nonimmune serum
(dotted line) and specific antisera (solid line) are shown for both CD46 and
CD55. CD46 and CD55 were also demonstrated on PTEC by indirect im-
munofluorescence (B and D, respectively).
FIGURE 7. The role of CD55 in bacterial interalization. The effect on
CD55 expression on PTEC of PI-PLC treatment is shown in A. Cells
treated with high-dose PI-PLC were used to assess internalization of J96 in
the presence of NHS (B). Treatment with PI-PLC significantly reduces Dr
fimbriated E. coli internalization in a concentration-dependent manner (p	
0.0018; one-way ANOVA) (C).
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Discussion
The results presented here offer several key insights into the mech-
anism of invasion of the human urinary tract by pathogenic E. coli.
A previous study has shown that the murine urinary tract is sus-
ceptible to infection by complement resistant E. coli that use C3 to
enhance infection of the upper urinary tract (19). Our current study
establishes the relevance of this complement-mediated internaliza-
tion to human UTI. First, we show that human renal tract epithelial
cells demonstrate complement-mediated internalization. Second,
we demonstrate an increase in the concentration of C3 in infected
urine permissive for this effect. Third, our data suggest that the
human complement regulatory protein, CD46 (MCP), is the likely
receptor on human urinary tract epithelium that mediates the in-
ternalization of opsonized E. coli.
Internalization of uropathogenic bacteria by epithelial cells has
been recognized for some time (3). However, the potential for
internalization to influence the outcome of infection is only now
becoming clear. Intracellular bacteria, persistent within the urinary
tract, are protected from the host innate immune response. Bacteria
can proliferate intracellularly, developing into pod-like structures
that can act as a source of recurrent infection (10). Internalization
may also provide a route by which bacteria can access deeper
structures and establish tissue-invasive infection. Bacterial fim-
briae appear to be essential for internalization, not only mediating
binding but also promoting the intracellular cytoskeletal reorgani-
zation required to internalize the bacteria (35). Type 1 fimbriae, in
particular, have been implicated in this process (9, 35).
As with other studies, we found bacterial internalization occurred in
the absence of complement activation, suggesting that complement is
nonessential for this process. However, the rate of uptake is increased
10-fold when the bacteria are preopsonized with complement or when
complement is added at a later stage during the incubation with target
epithelial cells. Binding of bacteria to epithelial cells is also increased
by C3 opsonization. It is possible that the increased internalization of
opsonized bacteria simply reflects greater bacteria–cell contact. How-
ever, we go on to show that internalization involves a specific ligand–
receptor interaction.
Our data suggest that bacterium-bound C3 interacts with CD46 on
the epithelial cell surface, presumably transducing an intracellular
signal and resulting in increased internalization. CD46 is recognized
FIGURE 8. The role of CD46 in bacterial interalization. The effect of CD46 siRNA transfection on PTEC CD46 mRNA levels by RT-PCR (A) and
protein levels by Western blot (B) are shown. Inhibition was dose dependent. Cells transfected with CD46 siRNA at a fixed (100 nM) (C) or variable (D)
siRNA concentration were assessed for the capacity to internalize bacteria in the presence of serum (n 	 3, representative of replicate experiments).
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as the cellular receptor for many pathogens, including measles virus
(36), human herpesvirus 6(24), some adenovirus strains, Group A
Strepococci (25), and Neisseria species (37). Binding of these patho-
gens to CD46 transduces a signal through the cytoplasmic tail of
CD46. There are two potential cytoplasmic tails of CD46 (Cyt 1 and
Cyt 2) that are generated by differential splicing and appear to have
different roles in signal transduction. The cytoplasmic tail of CD46
can be phosphorylated (38) with subsequent activation of both kinases
(39) and phosphatases (40). However, the exact signaling pathway(s)
activated through CD46 is incompletely understood and may differ in
different cell types.
The CD46-mediated internalization described in this report dif-
fers from those previously described in that in this case host de-
rived C3 is used by the organism to engage CD46. Exploitation of
C3 by cell-invasive bacteria has been described with several or-
ganisms. For example, C3-opsonized Mycobacterium tuberculosis
(41), Neisseria gonorrhoea (21), and the HIV (20) exhibit facili-
tated entry into macrophages and epithelial cells. These pathogens
use surface-bound C3 to engage the classical opsonic receptors, in
particular CR3. However, we were unable to identify these recep-
tors on urinary tract epithelial cells by either FACS or PCR anal-
ysis. Instead, our data, using gene silencing and competitive block-
ing, suggest that bacterium-bound C3b-cell surface CD46 was
responsible for this effect. Similarly, it has been suggested that
CD46 may mediate the uptake of C3 opsonized Klebsiella pneu-
moniae into pulmonary epithelial cells. In contrast, CD55 does not
appear to mediate internalization of opsonized E. coli. This is de-
spite its known capacity to mediate the internalization of Dr fim-
briated strains, which was again demonstrated in this report.
For this process to occur in vivo, uropathogenic E. coli would
need to be opsonized in the urinary space. The urine of healthy
individuals contains very little C3. However, as shown in this
study, the level of urinary C3 increases significantly during infec-
tion, possibly as a result of LPS-mediated stimulation of local ep-
ithelial synthesis of C3 or due to transepithelial leak of serum
complement proteins. The local production of C3 may originally
have served as an important defense against complement-sensitive
organisms. However, the majority of pyelonephritic isolates are
resistant to complement lysis, suggesting selective pressure and,
therefore, a fundamental role for complement. It appears that com-
plement-resistant strains have manipulated this system of defense,
resulting in a mechanism by which pathogens can potentially
evade other extracellular immune defense mechanisms.
The results described in the present study show that intracellular
infection of human epithelial cells by urinary tract E. coli may be
mediated by the complement system. Although our results are
compatible with either a protective mechanism clearing bacteria
from the urinary tract or a mechanism for enhancing the pathoge-
nicity of E. coli, the published data in mice favor a pathogenic
effect of complement use. Mice deficient in the complement com-
ponent C3 have striking resistance to ascending infection of uri-
nary tract. In fact, 10% of C3-null mice with bladder inoculation
of E. coli J96 develop ascending infection, compared with 60% of
wild-type mice, consistent with a benefit for the organisms in the
presence of urinary opsonization (19).
In conclusion, our results depict a novel mechanism of intraepi-
thelial invasion by a common urinary pathogen that is dependent
on the detection of bound C3 by the complement regulatory pro-
tein, CD46. Based on previous research in mice, it is likely that this
complement-mediated uptake enhances the pathogenicity of the
organism. C3 opsonization acts in conjunction with fimbrial ad-
hesins to maximize cell invasion. Novel approaches to the treat-
ment of E. coli infection depend on understanding the mechanism
of infection, including how host factors, such as the complement
system, are exploited by uropathogenic bacteria.
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